Sudarshan Pharma Expands US Footprint; Incorporates Wholly-Owned Subsidiary in Delaware
New Delhi [India], June 11: Shares of Sudarshan Pharma Industries Limited are likely to remain in focus after the company announced the incorporation of a wholly-owned subsidiary in the United States as part of its global expansion strategy.
In a regulatory filing dated June 10, 2026, the company informed stock exchanges that Sudarshan Industries Inc. (Sudarshan USA) was incorporated on June 5, 2026, in Delaware, United States. The newly formed entity will operate as a 100% subsidiary of Sudarshan Pharma Industries and is expected to strengthen the company’s presence in the world’s largest pharmaceutical market.
The company has subscribed to 1 crore shares of Sudarshan USA at a face value of US$0.00001 per share, amounting to a total investment of US$100 (approximately ₹9,600), thereby acquiring the entire paid-up share capital of the subsidiary.
According to the filing, Sudarshan USA will engage in the manufacture, processing, import, export, marketing and distribution of pharmaceutical products, active pharmaceutical ingredients (APIs), nutraceuticals, healthcare products, specialty chemicals, vaccines and related products.
The company stated that the key objective behind the incorporation is to expand its customer base in the United States, thereby enhancing its international business opportunities and strengthening its global footprint.
The investment will be made in cash and is subject to compliance with applicable overseas investment regulations under the Foreign Exchange Management Act (FEMA) and the Reserve Bank of India’s automatic route framework.
As per the disclosure, Sachin Mehta, Joint Managing Director, has been appointed as the first director of Sudarshan USA. The incorporation marks another step in Sudarshan Pharma’s international growth strategy as it seeks to deepen its reach in key overseas markets.
Disclaimer: This article is for informational purposes only and does not constitute financial advice.
